Pleginterferon-α-2a (40kD) -: A review of its use in the management of patients with chronic hepatitis B

被引：8

作者：

Robins, GW ^{[1
]}

Scott, LJ ^{[1
]}

Keating, GM ^{[1
]}

机构：

[1] Adis Int Ltd, Auckland, New Zealand

来源：

DRUGS | 2005年 / 65卷 / 06期

关键词：

D O I：

10.2165/00003495-200565060-00010

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Subcutaneous peginterferon-alpha-2a (40kD) [Pegasys((R))] is an effective and reasonably well tolerated treatment for the management of patients with hepatitis B e antigen (HBeAg)-negative or -positive chronic hepatitis B. It was significantly more effective than lamivudine monotherapy at inducing sustained virological response and ALT normalisation in both HBeAg-negative and -positive patients. Notably, the addition of lamivudine to peginterferon-alpha-2a (40kD) conferred no additional benefit versus peginterferon-alpha-2a (40kD) monotherapy. Moreover, in HBeAg-positive patients significantly more peginterferon-alpha-2a (40kD) recipients experienced HBeAg seroconversion than lamivudine recipients. The position of peginterferon-alpha-2a (40kD) relative to other treatment options remains to be fully determined. In the meantime, this agent appears to be a valuable new option for the management of patients with HBeAg-negative or -positive chronic hepatitis B.

引用

页码：809 / 825

页数：17

共 51 条

[1]

Bristol Myers Squibb, BRIST MYERS SQUIBB S

[2] A randomized, controlled trial of combination therapy for chronic hepatitis B:: Comparing pegylated interferon-α2b and lamivudine with lamivudine alone [J].